Ascendis Pharma A/S Appoints Scott T. Smith as Chief Financial Officer
"We are pleased to welcome Scott to the executive management team," commented
Mr. Smith stated, "I am thrilled to join Ascendis at this critical juncture. I am extremely impressed by the company's technology and deep pipeline, its focus on patient benefits, and the quality of the team. It is a privilege to join such an accomplished group of dedicated professionals."
Mr. Smith most recently served as Director of the
About
Additionally,
The TransCon technology combines the benefits of prodrug and sustained release technologies, and is the key driver of
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) our product pipeline, including our plans to initiate a pivotal Phase 3 pediatric study of TransCon Growth Hormone in mid-2016, (ii) our plan to build an integrated commercial business, (iii) our work to advance our pipeline and establish our company as a leader in the rare disease endocrinology arena and (iv) the application of our TransCon technology to the creation of product candidates to address significant unmet medical needs in rare disease indications carrying substantial commercial potential. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make, including the following: unforeseen safety or efficacy results in our lead development program TransCon Growth Hormone or other development programs; unforeseen expenses related to the development of TransCon Growth Hormone or other development programs, general and administrative expenses, other research and development expenses and our business generally; delays in the development of TransCon Growth Hormone related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; and our ability to obtain additional funding, if needed, to support our business activities. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to our business in general, see our current and future reports filed with, or submitted to, the
Internal contact:
Chief Financial Officer
(650) 352-8389
ir@ascendispharma.com
Investor contact:
Westwicke Partners
(415) 513-1284
patti.bank@westwicke.com
Media contact:
SparkBioComm
(650) 739-9952
ami@sparkbiocomm.com
Logo - http://photos.prnewswire.com/prnh/20150824/260617LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ascendis-pharma-as-appoints-scott-t-smith-as-chief-financial-officer-300310217.html
SOURCE